FriedmannT, RoblinR. Gene therapy for human genetic disease?. Science, 1972; 175:949–955.
2.
WilsonJ. Lessons learned from the gene therapy trial for ornithinetranscarbamylase deficiency. Mol Genet Metab, 2009; 96:151–157.
3.
Kumar SandeepRB, MarkusicDM, BeswasM, et al.Clinical development of gene therapy: results and lessons learned from recent success. Mol Ther Methods Clin Dev, 2016; 3:16034.
4.
LaptevaL, Purohit-ShethT, SerabianM, et al.Clinical development of gene therapies: the first three decades and counting. Mol Ther Methods Clin Dev, 2020; 19:367–397.
5.
KesslerDA, SiegelJP, NoguchiPD, et al.Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med, 1993; 329:1169–1173.
6.
HalmeDG, KesslerDA. FDA regulation of stem-cell-based therapies. N Engl J Med, 2006; 355:1730–1735.
7.
CavagnaroJA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov, 2002; 1:469–475.
8.
CavagnaroJ. Pre-clinical development strategies for new medicines: are the correct questions being asked?. Regul Aff J, 2001; 12:3–4.
